What is the rolapitant patent (and what company originally developed it)?
Rolapitant is a drug candidate used for prevention of chemotherapy-induced nausea and vomiting (CINV). Patents typically cover the specific active ingredient, its formulations (how it’s made and delivered), and related medical-use claims. The key patent landscape depends on which country you mean (US, EP, JP, etc.) and whether you’re looking for the “active ingredient” patent, formulation patent, or use/combination patents.
Which patents are usually relevant for rolapitant, and what do they protect?
For a medicine like rolapitant, patent filings commonly fall into these groups:
- Composition-of-matter patents that claim the molecule itself.
- Formulation patents that claim how rolapitant is prepared (for example, specific dosage forms).
- Method-of-use patents that claim treatment of CINV (or specific patient and dosing scenarios).
- Secondary patents that may claim particular salt forms, polymorphs, or stability/processing steps.
Which exact documents apply can differ by jurisdiction and by how the patent offices interpret and grant claims.
When do rolapitant patents expire?
Patent expiry depends on:
- the filing date of the earliest priority application,
- whether the patent term was extended (for example, regulatory extensions like Supplementary Protection Certificates in Europe, or pediatric exclusivity in the US),
- whether additional related patents exist that provide later “last-to-expire” protection for certain claims.
Without the specific country and (ideally) the reference drug product name, it isn’t possible to state an accurate rolapitant expiration date.
Is rolapitant still covered by patent protection today?
This also depends on jurisdiction and on which specific claims you’re tracking. Some parts of the portfolio may expire earlier (for example, composition patents), while other claims (formulation or use) may remain enforceable longer.
Are there challenges from generics or biosimilar-style competition?
If a rolapitant product has later-expiring patents, generic challengers often try to either:
- design around protected claims (so they don’t infringe), or
- challenge validity (arguing claims are not novel/obvious, or otherwise defective),
- or wait for the last-to-expire patent to run out.
Whether any challenges exist for rolapitant requires checking the relevant patent registers and any related litigation in the target country.
What do you need to find the exact rolapitant patent number?
To identify the correct patents and expiry, you need at least one of the following:
- the target country (US, EP, JP, etc.),
- the patent database you want (for example, USPTO, Espacenet/EPO, JPO),
- the brand/product name associated with rolapitant in that country,
- or a starting point such as an application/publication number.
If you tell me the country and (if you have it) the rolapitant product/brand name, I can narrow to the specific patent documents and their likely expiry dates.
Quick check: which rolapitant do you mean?
“Rolapitant” can also appear in multiple patent families over time (early molecule claims and later refinements). Confirming the jurisdiction and product name is the fastest way to avoid listing unrelated patents.
---
If you reply with the country (e.g., US or EP) and the drug/product name you care about, I can help you pin down the specific rolapitant patent(s) and what each one covers.
Sources
No sources were provided with your question, so I can’t cite specific rolapitant patent documents or dates yet.